Monographie - Tigecycline - Stabilis 4.0

Zadnji put ažurirano :
19/11/2024

antibiotik

Tigecycline

injekcija

Stabilizacija rješenja

Stabilnost mješavine

Stabilizacijski faktor

Kompatibilnosti

način davanja lijeka

Bibliografija

pdf

Kemijska struktura

Nekomercijalni

Nekomercijalni

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Eticina	Meksiko
Grexyl	Meksiko
Linicetil	Meksiko
Mrsacin	Turska
Tecygen	Čile
Tigecid	Turska
Tigecilina	Argentina, Čile, Ekvador
Tigecycline	Kanada
Tigetop	Čile
Tizoxim	Argentina
Tygacil	Argentina, Austrija, Belgija, Čile, Danska, Ekvador, Finska, Francuska, Grčka, Irska, Island, Italija, Japan, Kanada, Kolumbija, Luksemburg, Madžarska, Malezija, Meksiko, Nizozemska, Njemačka, Norveška, novi Zeland, Peru, Poljska, Portugal, Rumunjska, S A D, Saudijska Arabija, Španjolska, Švedska, Švicarska, Turska, Ujedinjeni Arapski Emirati, Velika Britanija, Venecuela
Zomiprerin	Peru

Bibliografija

injekcija

Bibliografija : Tigecycline

	Vrsta	Publikacija
2262	Časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratorija	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Časopis	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorija	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratorija	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratorija	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratorija	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Časopis	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Časopis	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Časopis	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Časopis	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Časopis	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales